BRAF and neoplasm: First, it is based on a large dataset for a BRAF-V600E-mutation-driven subset of CRC, from a phase 3 clinical trial with integrated tumor and ctDNA analyses via full WES/WTS sequencing and ctDNA genomic profiling.